Free press releases distribution network?

Agency / Source: Sinclair & Co.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



OsoBio Promotes Bob Cashman to Vice President of Business Development - OsoBio promotes Bob Cashman to vice president of business development - OsoBio.com
OsoBio Promotes Bob Cashman to Vice President of Business Development

 

PRZOOM - /newswire/ - Raleigh, NC, United States, 2012/09/18 - OsoBio promotes Bob Cashman to vice president of business development - OsoBio.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Robert “Bob” Cashman has been promoted to vice president of business development at OSO BioPharmaceuticals Manufacturing, LLC.

In his new role, Cashman is responsible for developing and executing strategies to expand the company’s injectable pharmaceutical contract manufacturing business. He also will oversee existing and potential customer relationships, manage pricing structures, and direct strategic corporate alliances.

Cashman, who joined OsoBio in 2009, previously served as director of new business development for the company’s East Coast market. He steps into a position vacated by Milton Boyer, who was appointed president of OsoBio in February.

“Bob has consistently demonstrated a keen ability to foster existing and new client opportunities for OsoBio,” Boyer said. “As OsoBio continues to successfully grow as a CMO renowned for world-class customer care, project management and regulatory compliance, I know Bob will help us achieve the goals we’ve set for ourselves.”

With more than 20 years of experience in contract pharmaceutical and biotechnology manufacturing, Cashman is a board member of the Philadelphia Drug Exchange, the oldest continually active trade organization in the United States. A member of the Parenteral Drug Association, he also heads the scholarship committee for the Drug, Chemical and Associated Technologies Association (DCAT). Cashman holds a bachelor’s degree in business administration from Villanova University.

OsoBio (osobio.com) is a contract manufacturing organization (CMO) that specializes in delivering injectable sterile liquid, suspension and lyophilized biologic and pharmaceutical products to the pharmaceutical industry. The company offers significant knowledge and experience in late phase clinical products and successfully taking them to commercialization. In the history of its Albuquerque, N.M., facility, OsoBio has manufactured more than 250 distinct commercial presentations in every major therapeutic category.

The U.S. Drug Enforcement Administration (DEA) has granted OsoBio registrations for Schedule II through V controlled substances.

Responsiveness, attention to detail and clear communication are the hallmarks of OsoBio’s client care. Its employees are industry veterans who provide innovative solutions to clients’ most difficult projects.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Sinclair & Co.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


OsoBio Promotes Bob Cashman to Vice President of Business Development

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Karen Stinneford - Sinclair-Co.com 
919-833-9102 kys[.]sinclair-co.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Sinclair & Co. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Sinclair & Co. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
Somatuline® Autogel® 120 Mg Receives Japanese Approval for A New Indication for the Treatment of Gastro-entero-pancreatic Neuroendocrine Tumors
OTC Topical Drugs Market Size will Grow Profitably in the Near Future 2017-2025 Finds PMR
Bioinformatics Market Size to Expand at 20.4% CAGR through 2020 Reports Persistence Market Research
Australia Nitric Acid Market Expected to Reach at Value of $1.3B by 2024 End Says PMR

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  BizJobs.com

Visit  S&A Capital Partner Ltd







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today